Provectus Biopharmaceuticals, Inc.
Income Statement
| Line Item | FY2011 |
|---|---|
| Revenue | $0 |
| Cost of Revenue | $0 |
| Gross Profit | $0 |
| Gross Margin | — |
| Operating Expenses | |
| Research & Development | $8.8M |
| SG&A Expense | $12.0M |
| Operating Income | $-21.4M |
| Operating Margin | — |
| Interest Expense | $0 |
| Pretax Income | — |
| Income Tax Expense | — |
| Net Income | $-19.4M |
| Net Margin | — |
| EPS (Basic) | — |
| EPS (Diluted) | — |
| Shares Outstanding (Basic) | 110.6M |
| Shares Outstanding (Diluted) | 110.6M |
| Dividends Per Share | — |